Methylene blue retains in vitro activity against early ring-stage artemisinin-resistant Plasmodium falciparum
3
item.page.dc.date.issued
2026-12-01
item.page.dc.type
item.page.dc.identifier.eissn
14752875
item.page.dc.identifier.doi
item.page.dc.identifier.scopus
2-s2.0-105043510505
item.page.dc.identifier.pmid
42087189
item.page.oaire.citation.title
Malaria Journal
item.page.oaire.citation.volume
25
item.page.oaire.citation.issue
1
item.page.dc.rights.holder
SCOPUS
item.page.dc.identifier.citation
Malaria Journal Vol.25 No.1 (2026)
punsarn.item.page.citation
Verdier O., Christensen P., Kaewkanya C., Kobphan P., Beau C., Phyo A.P., Imwong M., Chotivanich K., White N.J., Nosten F., Chaumeau V. Methylene blue retains in vitro activity against early ring-stage artemisinin-resistant Plasmodium falciparum. Malaria Journal Vol.25 No.1 (2026). doi:10.1186/s12936-026-05928-7 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/117845
item.page.dc.title
Methylene blue retains in vitro activity against early ring-stage artemisinin-resistant Plasmodium falciparum
item.page.dc.contributor.author
item.page.oairecerif.author.affiliation
item.page.dc.contributor.correspondence
item.page.dc.contributor.other
item.page.dc.description.abstract
Artemisinin resistance in Plasmodium falciparum is now well established in three continents and challenges the efficacy of antimalarial drug regimens. This study examined whether methylene blue, an ancient antimalarial drug with a broad spectrum of activity against Plasmodium blood stages, retains its activity against the young rings of artemisinin-resistant parasites. Clinical isolates carrying kelch13 wild type (n = 3), R561H (n = 9), or P441L (n = 10) genotypes were tested with a modified ring survival assay whereby 0- to 3-h post-invasion rings were exposed to a range of methylene blue concentrations. Ring survival was analysed with a Bayesian mixed effects E<inf>max</inf> model accounting for variability across isolates and experimental replicates. Methylene blue suppressed ring-stage survival at low nanomolar concentrations with no evidence of kelch13-mediated cross-resistance: the mean 50% inhibitory concentration (IC<inf>50</inf>) estimates were 23 nM (95% credible interval [CrI]: 15 to 37) for wild type, 27 nM (95% CrI: 21 to 36) for R561H and 14 nM (95% CrI: 10 to 20) for P441L. These findings indicate that methylene blue remains active in vitro against ring-stage artemisinin-resistant parasites.